HC Wainwright Reaffirms Buy Rating for Jaguar Health (NASDAQ:JAGX)

HC Wainwright reiterated their buy rating on shares of Jaguar Health (NASDAQ:JAGX) in a research note released on Monday, April 15th, Zacks.com reports.

Separately, ValuEngine lowered shares of Jaguar Health from a buy rating to a hold rating in a research report on Thursday, January 24th.

Shares of JAGX traded down $0.01 during trading hours on Monday, reaching $0.19. 3,002,100 shares of the company traded hands, compared to its average volume of 5,560,598. Jaguar Health has a 1-year low of $0.12 and a 1-year high of $3.20.

About Jaguar Health

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Featured Article: How is the LIBOR rate calculated?

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.